8-K: Harrow Completes Melt Pharma Acquisition, Eyes Sedation Market

Harrow, Inc. has completed its acquisition of Melt Pharmaceuticals, expanding its portfolio with non-opioid, non-IV sedation therapies.

Summary

• Harrow, Inc. completed the acquisition of Melt Pharmaceuticals, Inc. on November 17, 2025, for an initial cash consideration of approximately $4.3 million.
• Melt Pharmaceuticals is a clinical-stage company focused on non-opioid, non-IV therapies for sedation using the proprietary Zydis ODT (oral dissolving tablet) drug delivery platform.
• The acquisition includes product candidates MELT-210, MELT-300, and MELT-400, with global patent coverage and potential applications in ophthalmology, gastroenterology, dental care, and various outpatient procedures.
• MELT-300, a sublingually delivered formulation of midazolam (3mg) and ketamine (50mg), is designed for rapid, predictable sedation without intravenous administration.
• MELT-300 previously demonstrated statistical superiority to midazolam alone in Phase 2 and Phase 3 clinical programs.
• Harrow aims to enter the multi-billion-dollar annual U.S. and global procedural sedation and anxiety market with these drug candidates.
• MELT-210, a sublingual dosage of midazolam (3mg), is also considered to have strong commercial potential due to its rapid uptake and short half-life.

Sentiment

Score: 8

Explanation: The filing announces the completion of a strategic acquisition with significant growth potential in a large market, supported by positive clinical trial data and a clear path to commercialization. The tone is highly optimistic, and the identified risks are standard for a pharmaceutical company.

Positives

• The acquisition strategically expands Harrow's portfolio into the multi-billion-dollar annual U.S. and global procedural sedation and anxiety market.
• MELT-300 offers a transformative opportunity as a potential FDA-approved non-opioid, non-IV sublingual sedation therapy, addressing a significant healthcare demand to reduce opioid exposure.
• MELT-300 demonstrated statistical superiority to midazolam alone in its Phase 2 and Phase 3 clinical programs.
• The Zydis ODT platform provides global patent coverage and broad application potential across multiple medical specialties.
• Harrow can leverage its existing commercial infrastructure and MKO Melt customer network (over 800 U.S. ophthalmic institutions) for MELT-300's commercialization.
• MELT-210, another drug candidate, is believed to have strong commercial potential due to its advantageous characteristics, including rapid uptake and short half-life.
• The MELT-300 program was subject to a Special Protocol Assessment (SPA), confirming the completed Phase 3 study design supports a future regulatory submission.

Risks

• Risks related to liquidity or results of operations.
• Ability to successfully implement the business plan, develop and commercialize products and product candidates in a timely manner or at all.
• Ability to identify and acquire additional products, manage pharmacy operations, service debt, and obtain necessary financing.
• Ability to recruit and retain qualified personnel and manage any growth experienced.
• Ability to successfully realize the benefits of previous acquisitions and any other acquisitions and collaborative arrangements.
• Competition from pharmaceutical companies, outsourcing facilities, and pharmacies.
• General economic and business conditions, including inflation and supply chain challenges.
• Regulatory and legal risks, including litigation matters, and other uncertainties related to pharmacy operations and the pharmaceutical business.
• Physician interest in and market acceptance of current and any future formulations and compounding pharmacies generally.

Future Outlook

Harrow plans to advance MELT-300 towards FDA approval and commercialization, targeting an NDA submission in H1 2027, potential FDA approval in H1 2028, and commercial launch in H2 2028. The company also intends to engage with the FDA to discuss next steps for the MELT-210 drug development program, aiming for a second product from the Melt portfolio.

Management Comments

• "The development of MELT-300 marks a defining milestone for Harrow – our first product taken from ideation to the brink of commercialization." Mark L. Baum, Chief Executive Officer of Harrow.
• "We’re incredibly excited about MELT-300’s potential to transform procedural sedation, reduce opioid exposure, and expand safe, accessible sedation options across medical specialties. It’s not just a scientific or commercial achievement – it’s a meaningful step forward for patients and for the US healthcare system." Mark L. Baum, Chief Executive Officer of Harrow.
• "In addition to the MELT-300 program, in parallel, our clinical development team is also excited to advance the MELT-210 drug candidate in procedural sedation, which we have rarely spoken about, but which nevertheless remains an important part of the rationale behind this acquisition." Amir Shojaei, Chief Scientific Officer of Harrow.
• "We believe MELT-210 will have strong commercial potential. We look forward to engaging with FDA to discuss next steps for this advanced drug development program, and in due course, to have a second product in the market from the Melt portfolio." Amir Shojaei, Chief Scientific Officer of Harrow.
• "I’ve relied on MKO Melt for years because it delivers what both clinicians and patients want – effective, needle-free sedation without opioids or the need for IV access. The workflow efficiencies and safety profile have made it a cornerstone of our surgical suite." Dr. Lawrence Woodard, M.D., Medical Director of Omni Eye Services of Atlanta.

Industry Context

The acquisition positions Harrow to capitalize on the growing demand for non-opioid, non-IV procedural sedation and anxiety management solutions. This trend is driven by the healthcare system's need to reduce opioid exposure and improve patient experience and workflow efficiency in various settings, including ophthalmology, gastroenterology, dental care, diagnostic imaging, and pre-anesthesia.

Comparison to Industry Standards

• MELT-300 builds on over a decade of real-world experience with MKO Melt, a compounded sublingual sedation product currently administered by over 800 U.S. ophthalmic institutions, primarily for cataract surgery.
• MELT-300 demonstrated statistical superiority to midazolam alone in Phase 2 and Phase 3 clinical programs.
• MELT-210 offers advantageous characteristics, including rapid uptake and short half-life, compared to current market alternatives.
• The goal is for MELT-300 to become the first FDA-approved, non-opioid, non-IV sublingual sedation therapy in the U.S.

Stakeholder Impact

• Shareholders: Potential for significant growth and increased value through market expansion and new product commercialization.
• Patients: Improved patient outcomes and experience through non-opioid, non-IV sedation options, reducing opioid exposure and expanding access to safe, convenient sedation.
• Clinicians/Healthcare System: Potential for workflow efficiencies and improved safety profiles in surgical suites and various outpatient settings.
• Employees: Integration of Melt Pharmaceuticals employees into Harrow's operations.

Next Steps

• Full integration of Melt Pharmaceuticals into Harrow's operations to ensure a seamless transition and accelerate progress.
• Initiating one non-clinical animal study and three pharmacokinetics (PK) studies to generate the balance of data necessary for an NDA package for MELT-300.
• Prepare and submit the New Drug Application (NDA) for MELT-300 in H1 2027.
• Engage collaboratively with the FDA through the regulatory review process, with potential approval in H1 2028.
• Execute commercial readiness and launch preparations for MELT-300 in H2 2028, including manufacturing scale-up, packaging, supply-chain validation, reimbursement, and market-access planning.
• Build on Harrow's established ophthalmic footprint to drive adoption of MELT-300 initially in cataract and other ophthalmic procedures, followed by expansion into additional outpatient and in-office settings.
• Engage with the FDA to discuss next steps for the MELT-210 drug development program.

Key Dates

Recommendation

The completion of the Melt Pharmaceuticals acquisition is a highly strategic move for Harrow, positioning the company to enter the multi-billion-dollar procedural sedation market with innovative, non-opioid, non-IV therapies. MELT-300 has demonstrated statistical superiority in clinical trials and has a clear, albeit future, path to FDA approval and commercialization, leveraging Harrow's existing infrastructure. The potential for a second product, MELT-210, further strengthens the long-term growth outlook. This acquisition represents a significant value-add and a strong growth driver for Harrow.

Keywords

Harrow, Melt Pharmaceuticals, acquisition, ophthalmic, sedation, non-opioid, non-IV, MELT-300, MELT-210, Zydis ODT, pharmaceutical, clinical-stage, FDA approval, procedural sedation, anxiety management, midazolam, ketamine